The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment…
Articles by José Lopes, PhD
Health Canada has approved Orkambi (ivacaftor/lumacaftor) to treat preschoolers with cystic fibrosis (CF) who carry the F508del mutation in…
Preschoolers with cystic fibrosis (CF) treated with inhaled hypertonic saline in a clinical trial showed significant improvement in lung function,…
Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved…
A protein toxin called Tse7 is used by Pseudomonas aeruginosa to kill neighboring bacteria, and may help explain why…
Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitro efficacy against multidrug-resistant Pseudomonas aeruginosa collected from the sputum of cystic…
The U.S. Food and Drug Administration gave positive feedback to the design of AmpliPhi Biosciences’ two proposed clinical trials…
Blood levels of D-lactate may be markers of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF),…
Orkambi (lumacaftor/ivacaftor), a treatment for cystic fibrosis (CF) patients in Australia age 6 and up, is closer to being…
Arcturus Therapeutics’ RNA-based approach enables the production of healthy CFTR — the protein whose dysfunction is key in cystic…